

AD-A269 667



13



PUBLICATION REPORT

1757

35/93

PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS
IN PREGNANT WOMEN IN EGYPT

BY

Nassef F. Hassan and Amira Kotkat

~~RESTRICTED~~
Approved for public release
Distribution unlimited

Original and copies
to be maintained in black and
white

U.S. NAVAL MEDICAL RESEARCH UNIT NO. 3
(CAIRO, ARAB REPUBLIC OF EGYPT)
PSC 452, BOX 5000
FPO AE 09835-0007

93-21487

93 9 14 162



Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	2D

DTIC QUALITY INSPECTED 1

Prevalence of Antibodies to Hepatitis C Virus in Pregnant Women in Egypt

Colleagues—Hepatitis C virus (HCV) infection has been shown to be responsible for 90% of posttransfusion hepatitis [1]. It is estimated that 50% of those infected with HCV will develop chronic hepatitis, of whom 20% will develop chronic active hepatitis, cirrhosis, hepatocellular carcinoma, or a combination [2]. The prevalence of antibodies to HCV (anti-HCV) in blood donors in the United States and Europe is low (0.047%–1.2%) [3, 4]. A similar study of Egyptian blood donors at Riyadh, Saudi Arabia, using first-generation ELISA and polymerase chain reaction has revealed an HCV infection prevalence of 19.2% and 13.6%, respectively, the highest in comparison with subjects from other countries in the region [5]. Using a second-generation ELISA and second-generation RIBA (Ortho Diagnostic Systems, Raritan, NJ), a recent study of the prevalence of anti-HCV among 2167 Egyptian university student blood donors revealed a prevalence of 9.6% [6].

Although parenteral transmission has been described as the major route of HCV transmission, HCV can also be transmitted

vertically from infected mothers to their newborns [7]. To assess whether vertical transmission could potentially contribute to the high prevalence of HCV in Egypt, we determined the prevalence of anti-HCV in pregnant women. We enrolled 1536 pregnant mothers (age range, 17–45 years; mean, 27) attending an antenatal outpatient clinic. Sera collected during the second and third trimesters of pregnancy were tested for anti-HCV using a second-generation ELISA (Abbott Laboratories, Abbott Park, IL), and positive ELISA results were confirmed by second-generation RIBA. These two tests detect anti-HCV to structural and nonstructural proteins of HCV using C-100-3, 5-1-1, C33c, and C22-3 recombinant antigens.

There were 101 serum samples (6.5%) repeatedly positive (three times) by ELISA. RIBA confirmed 67 samples (66.3%) as positive, 21 (20.2%) were indeterminate, and 13 (12.8%) were negative. The 13 RIBA-negative samples were only weakly reactive by ELISA (sample optical density/cutoff optical density was <1.8). The 21 RIBA-indeterminate results were from 16 samples positive for C22-3 antigen only, 3 samples reactive to C33c only, and 2 samples reactive to C-100-3 only. Overall RIBA-confirmed anti-HCV were detected in 4.3% of normal healthy pregnant women in this study of Egyptian women. This prevalence of anti-HCV is higher than was reported from France, where anti-HCV prevalence was 0.9% in pregnant women [8]. In summary, we found that HCV seroprevalence in pregnant women in Egypt is high. Additional studies of babies born to infected mothers should be done to assess to what extent vertical transmission contributes to the high prevalence of HCV infection in Egypt.

Nassef F. Hassan and Amira Kotkat

Hepatitis and HIV Research Branch, Virology Division, US Naval Medical Research Unit 3, Cairo; Department of Tropical Medicine and Hygiene, High Institute of Public Health, Alexandria University, Alexandria, Egypt

Informed consent was obtained from all enrolled subjects, and guidelines of the US Department of Health and Human Services and those of the authors' institutions for protection of human subjects were followed.

The opinions and assertions contained herein are the private ones of the authors and are not to be construed as official or as reflecting the views of the US Departments of the Navy or Defense or the US government.

Financial support: Naval Medical Research and Development Command, Bethesda, Maryland, Work Unit no. 3M162770A870.AR.322.

Reprints or correspondence: Research Publications Branch, US NAV-MEDRSCHU Three Code 304D, PSC 452 Box 5000, FPO AE 09835-0007.

The Journal of Infectious Diseases 1993;168:248–9

© 1993 by The University of Chicago. All rights reserved.

0022-1899/93/6801-0045\$01.00

References

1. Dawson GJ, Lesniewski RR, Stewart JL, et al. Detection of hepatitis C virus in U.S. blood donors. *J Clin Microbiol* **1991**;29:551-6.
2. Colombo M, Choo QL, Del Ninno E, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. *Lancet* **1989**;2:1006-8.
3. Garson JA, Clewley JP, Simmonds P, et al. Hepatitis C viraemia in United Kingdom blood donors. *Vox Sang* **1992**;62:218-23.
4. Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. *Ann Intern Med* **1991**;115:443-9.
5. Saeed AA, Al-Admawi AM, Al-Rasheed A, et al. Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh. *Lancet* **1991**;338:459-60.
6. Kamel MA, Ghaffar YA, Waset MA, et al. High HCV prevalence in Egyptian blood donors. *Lancet* **1992**;340:427.
7. Thaler MM, Park CK, Landers DV, et al. Vertical transmission of hepatitis C virus. *Lancet* **1991**;338:17-8.
8. Roudot-Thoraval F, Guillot I, Huriaux C, et al. Serological and biochemical follow-up of newborns from mothers with hepatitis C virus infection. In: Program of the 3rd International Symposium on HCV. Strasbourg, France, 1991.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 1993	3. REPORT TYPE AND DATES COVERED	
4. TITLE AND SUBTITLE Prevalence of Antibodies to Hepatitis C Virus in Pregnant Women in Egypt			5. FUNDING NUMBERS PE- 62770A WU- 3M162770A870.AR.322	
6. AUTHOR(S) Hassan, Nassef F. and Kotkat, Amira				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) U.S. Naval Medical Research Unit No. 3 PSC 452, Box 5000 FPO AE 09835-0007			8. PERFORMING ORGANIZATION REPORT NUMBER 35/93	
9. SPONSORING MONITORING AGENCY NAME(S) AND ADDRESS(ES) Naval Medical Research and Development Command, National Naval Medical Center Building 1, Tower 12 Bethesda, MD 20889-5044			10. SPONSORING MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Published in: J. Infect. Dis., 168:248-249, 1993; Acc. No. 1757.				
12a. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; Distribution is unlimited.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Please see attached.				
14. SUBJECT TERMS Hepatitis C; Prevalence; Antibodies; Pregnant women; Egypt.			15. NUMBER OF PAGES 2	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED	20. LIMITATION OF ABSTRACT	